Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114212 | 0.93 | KDR (0.44) | SRCMAOAMAOBKDRPDGFRB | |
| SCHEMBL2117957 | 0.88 | MEN1 (0.46) | SRCALKKDRPDGFRBFGFR1 | |
| SCHEMBL1673441 | 0.88 | ALK (0.52) | LRRK2SRCALKKDRPDGFRB | |
| SCHEMBL2114981 | 0.86 | CHEK1 (0.40) | SRCKDRPDGFRBFGFR1EGFR | |
| SCHEMBL2114657 | 0.85 | CHEK1 (0.41) | SRCKDRPDGFRBFGFR1EGFR | |
| SCHEMBL2118294 | 0.85 | MEN1 (0.42) | LRRK2SRCALKKDRPDGFRB | |
| SCHEMBL2114228 | 0.85 | SRC (0.45) | SRCALKKDRPDGFRBFGFR1 | |
| SCHEMBL2116233 | 0.85 | FLT3 (0.41) | LRRK2RAF1ALKAKT2KDR | |
| SCHEMBL2114010 | 0.83 | CHEK1 (0.39) | SRCKDRPDGFRBFGFR1EGFR | |
| SCHEMBL393773 | 0.82 | TLK2 (0.48) | AKT2KDRPDPK1TLK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | LRRK2 580/4885RAF1 238/4885SRC 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.